Table 1.

Eligibility criteria applied in this study.

	Inclusion Criteria	Exclusion Criteria
Population	Rodents (offspring and/or adults); hypothalamic cell lines; or primary hypothalamic cell culture.	Other cells than hypothalamic; non-rodents and studies involving human subjects.
Intervention	High-fat feeding; genetic models of obesity; treatment with fatty acids; treatment with cytokines; treatment with sphingolipids (ceramide or sphingosine-1-phosphate).	Other genetic backgrounds; animals with protein restriction or receiving any other treatment.
Comparison	Sphingolipid levels (ceramide and sphingosine-1-phosphate); fasting.	Studies related to ganglioside metabolism.
Outcomes	Alterations in sphingolipid metabolism following disturbances in energy balance control. Primary outcomes: sphingolipid level (ceramide and sphingosine -1-phosphate). Secondary outcomes: Body weight, food intake, energy expenditure assessments, neuropeptides levels, and inflammatory markers.	Other outcomes not relevant to energy balance control.
Type of publication	Original article	Nonoriginal article (reviews, conference abstracts).
Other selection criteria	Studies following these main characteristics were included: animal and cell culture studies from 1990 until 2020. The articles needed to be published on these databases: PubMed, Embase, Web of Science, and Scopus. Keywords searched: sphingolipid and hypothalamus.	Non-English language.